Author:
Yépez Vicente A.,Gusic Mirjana,Kopajtich Robert,Mertes Christian,Smith Nicholas H.,Alston Charlotte L.,Ban Rui,Beblo Skadi,Berutti Riccardo,Blessing Holger,Ciara Elżbieta,Distelmaier Felix,Freisinger Peter,Häberle Johannes,Hayflick Susan J.,Hempel Maja,Itkis Yulia S.,Kishita Yoshihito,Klopstock Thomas,Krylova Tatiana D.,Lamperti Costanza,Lenz Dominic,Makowski Christine,Mosegaard Signe,Müller Michaela F.,Muñoz-Pujol Gerard,Nadel Agnieszka,Ohtake Akira,Okazaki Yasushi,Procopio Elena,Schwarzmayr Thomas,Smet Joél,Staufner Christian,Stenton Sarah L.,Strom Tim M.,Terrile Caterina,Tort Frederic,Van Coster Rudy,Vanlander Arnaud,Wagner Matias,Xu Manting,Fang Fang,Ghezzi Daniele,Mayr Johannes A.,Piekutowska-Abramczuk Dorota,Ribes Antonia,Rötig Agnès,Taylor Robert W.,Wortmann Saskia B.,Murayama Kei,Meitinger Thomas,Gagneur Julien,Prokisch Holger
Abstract
Abstract
Background
Lack of functional evidence hampers variant interpretation, leaving a large proportion of individuals with a suspected Mendelian disorder without genetic diagnosis after whole genome or whole exome sequencing (WES). Research studies advocate to further sequence transcriptomes to directly and systematically probe gene expression defects. However, collection of additional biopsies and establishment of lab workflows, analytical pipelines, and defined concepts in clinical interpretation of aberrant gene expression are still needed for adopting RNA sequencing (RNA-seq) in routine diagnostics.
Methods
We implemented an automated RNA-seq protocol and a computational workflow with which we analyzed skin fibroblasts of 303 individuals with a suspected mitochondrial disease that previously underwent WES. We also assessed through simulations how aberrant expression and mono-allelic expression tests depend on RNA-seq coverage.
Results
We detected on average 12,500 genes per sample including around 60% of all disease genes—a coverage substantially higher than with whole blood, supporting the use of skin biopsies. We prioritized genes demonstrating aberrant expression, aberrant splicing, or mono-allelic expression. The pipeline required less than 1 week from sample preparation to result reporting and provided a median of eight disease-associated genes per patient for inspection. A genetic diagnosis was established for 16% of the 205 WES-inconclusive cases. Detection of aberrant expression was a major contributor to diagnosis including instances of 50% reduction, which, together with mono-allelic expression, allowed for the diagnosis of dominant disorders caused by haploinsufficiency. Moreover, calling aberrant splicing and variants from RNA-seq data enabled detecting and validating splice-disrupting variants, of which the majority fell outside WES-covered regions.
Conclusion
Together, these results show that streamlined experimental and computational processes can accelerate the implementation of RNA-seq in routine diagnostics.
Funder
Bundesministerium für Bildung und Forschung
Deutsches Zentrum für Herz-Kreislaufforschung
Deutsche Forschungsgemeinschaft
Wellcome Trust Centre for Mitochondrial Research
National Institute for Health Research
Agency for Medical Research and Development
Instituto de Salud Carlos III
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
Publisher
Springer Science and Business Media LLC
Subject
Genetics (clinical),Genetics,Molecular Biology,Molecular Medicine